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Alterations in cell metabolism are a characteristic of many
cancers. Cancer cells are metabolically rewired to support
their rapid growth (Kim and Dang, 2006; Vander Heiden
et al., 2009). The best-characterized metabolic phenotype
observed in tumor cells is aerobic glycolysis, also known as
the Warburg effect, which is a shift of ATP generation from
high efﬁcient oxidation phosphorylation to low efﬁcient gly-
colysis even under normal oxygen concentration (Gatenby
and Gillies, 2004; Warburg, 1956). Pyruvate kinase cat-
alyzes the ﬁnal step in glycolysis by transferring the phos-
phate from phosphoenolpyruvate (PEP) to ADP, thereby
generating pyruvate and ATP (Altenberg and Greulich, 2004;
Corcoran et al., 1976). In mammals, pyruvate kinase is en-
coded by two genes, PKLR and PKM (Noguchi et al., 1987).
PKM2 is one of the splicing variants from PKM gene, ex-
pressed in development and most cancers, and plays a
central role in tumorigenesis (Chaneton and Gottlieb, 2012;
Christofk et al., 2008; Yang and Lu, 2013; Yang et al.,
2012a).
The activity of PKM2 can be regulated by numerous
allosteric effectors and posttranslational modiﬁcations
(PTMs) that could change its conformation. For example,
binding to metabolites, such as fructose-1,6-bisphosphate
(FBP), can forge PKM2 into more active tetramer (Dom-
brauckas et al., 2005). Phosphorylation of PKM2 at tyrosine
105 inhibits the tetramer formation and pyruvate kinase
activity of PKM2 (Hitosugi et al., 2009). Moreover, acetylation
of residue K305 inhibits pyruvate kinase activity of PKM2 (Lv
et al., 2011). Interestingly, a patient-derivedmutationK422Rof
PKM2 (PKM2 K422R) was shown to decrease its pyruvate
kinase activity in Bloom Syndrome (BS) patients (Iqbal et al.,
2014). However, the detailed mechanisms underlying the
regulation of PKM2 activity by those PTMs and mutations
remain unclear. In this issue,Wang et al. (2015) demonstrated
a structure-basedmechanism for dynamic regulation of PKM2
by PTMs and a patient-derived mutation (Wang et al., 2015).
As reported in previous studies, PKM2 switches between
dimer and tetramer and tetramer formation is crucial for
PKM2 activation (Dombrauckas et al., 2005; Gui et al.,
2013). The gel-ﬁltration analyses of in vitro puriﬁed PKM2
proteins by Wang et al. showed a mixed population of PKM2
in monomer, dimer and tetramer. PKM2 WT prefers dimer
under normal condition and tends to form a more active te-
tramer in the presence of FBP. However, acetylation-mimic
mutant, PKM2 K305Q, mainly exists as a monomer, and
becomes a dimer upon FBP treatment. Either monomeric or
dimeric PKM2 K305Q shows much lower glycolytic activity
as determined by pyruvate kinase assay. Analyzing struc-
ture, they noticed that PKM2 K305Q loses the intermolecular
interactions on the A-A′ interface, which leads to the failure
to form tetramer. Y105E, a phosphorylation-mimic mutation,
was previously reported to inhibit PKM2 activity. In this study,
it was further conﬁrmed to prevent the FBP-induced active
tetramer formation by disrupting FBP association. Taken
together, these results further highlight the importance of the
tetramer formation in PKM2 activation and suggest that the
regulation of PKM2 oligomerization may be a general
mechanism to modulate PKM2 activity.
Further investigation indicates tetrameric PKM2 does not
always possess high activity. Gel-ﬁltration analysis by Wang
et al. shows that PKM2 K422R comprises of a signiﬁcantly
high population of tetramer. Nonetheless, much lower ac-
tivity than PKM2 WT was detected with this mutant as de-
termined by pyruvate kinase assay. This exemption makes it
inaccurate to predict its activity based on PKM2 oligomer-
ization. Interestingly, in the presence of FBP, PKM2 K422R
shows a signiﬁcant increase of its enzymatic activity and still
maintains its tetrameric conformation. This observation im-
plies that two types of PKM2 tetramers might exist with dif-
ferent activities. How do they differ from each other in
structure? A recent study from Morgan et al provides a clue
for further analysis (Morgan et al., 2010; Morgan et al.,
2013). They showed that phenylalanine stabilizes an inactive
T-state tetrameric conformer and inhibits PKM2, while FBP
shifts the equilibrium to the tetrameric active R-state. This
result leads to a hypothesis whether PKM2 K422R possess
© The Author(s) 2015. This article is published with open access at Springerlink.com and journal.hep.com.cn










similar conﬁrmation to T-state tetramer. To validate it, Wang
et al. analyzed the crystal structures of PKM2 K422R in the
presence or absence of FBP, and compared to R-state
PKM2, PKM2Oxalate, or T-state PKM2, PKM2Phe. They found
that PKM2 K422R_FBP shared R-state tetrameric confor-
mation with PKM2Oxalate, whereas PKM2 K422R adopted
T-state tetrameric conﬁrmation like PKM2Phe. R-state PKM2
is more active than T-state PKM2. More details about these
two states have been included in “Rock and Lock” model
proposed by Morgan et al. However, this model does not
reﬂect the dynamic regulation of PKM2. Wang et al. shows
that PKM2 tetramer is formed by intermolecular interactions
between four monomers on large (A-A′) and small (C-C′)
interfaces and each individual monomer adopts similar fold
with a root-mean-squared deviation of less than 0.6 Å.
Further comparison of crystal structure of different PKM2
proteins indicates that PKM2 undergoes a signiﬁcant con-
ﬁrmation change during the transition between R- and
T-state. Based on these observation, they proposed a
“seesaw” model to summarize conformational changes dur-
ing transitions between R-/and T-state PKM2.
PKM2 R399E was previously reported to lock PKM2 in
dimer and have low glycolytic activity (Gao et al., 2012).
However, in crystals, PKM2 R399E adopts the T-state con-
formation similar to PKM2Phe as shown by Wang et al. And
this mutation of PKM2 inhibits the formation of the R-state
conformation induced by FBP or PEP (R399E on monomer
A repels E396 on monomer A and E418 on monomer B on
the C-C′ interface). Consistently, PKM2 R399E is less active
than PKM2 WTand less tendency to form R-state tetramer in
the presence of FBP.
The important role of PKM2 in cancer makes PKM2 an
attractive therapeutic target for cancer treatment. However,
the complexity of PKM2 regulation enables multiple strate-
gies to targeting PKM2. Approaches to inhibit as well as to
activate PKM2 have been pursued. A chemical, TEPP-46
can enhance the intermolecular interactions on the A-A′ in-
terface and favor an R-state conformation to activate PKM2
(Anastasiou et al., 2012). The activation of PKM2 by
TEPP-46 ﬁnally rewired the metabolism of tumor cells to
catabolism and inhibited the xenograft tumor growth. This
result suggests a possibility to develop inhibitors or activa-
tors based on R-/T-state transition of PKM2.
Protein kinase activity of PKM2 has been recently rec-
ognized and plays critical roles in tumorigenesis (Gao et al.,
2012; Yang et al., 2012b; Yang et al., 2011). This spectacular
ability needs PKM2 located in nucleus. Upon EGFR activa-
tion, PKM2 was phosphorylated by ERK2, which recruits
Importin α5 to facilitate its nuclear translocation (Yang et al.,
2012c). In nucleus, PKM2 mainly exists as a dimer with high
activity of protein kinase and low activity of pyruvate kinase.
Interestingly, as shown by Wang et al. these dimers are
formed with the loss of intermolecular interaction on the C-C′
interface, suggesting that regulation on this interface may be
responsible for the switch from pyruvate kinase to protein
kinase. Catalytic core and substrate speciﬁcity remains to be
investigated.
Besides structural analysis of PKM2 regulated by PTMs,
Wang et al. also examined the correlation between thermal
stability and PKM2 activity. Thermal stability is the stability of
a molecule at high temperatures; i.e. a molecule with more
stability has more resistance to decomposition at high tem-
peratures. The thermal stability of PKM2 was previously re-
ported to correlate with its enzymatic activity (Morgan et al.,
2010). However, Wang et al. observed an inconsistence
when they performed thermal-shift assay with PKM2 WTand
its PTMs-mimic mutants. They found that PKM2 R399E and
PKM2 K422R are relatively more stable than PKM2 WT,
suggesting PKM2 activity could not be well determined by its
thermal stability either.
In conclusion, PKM2 activity is subject to complex al-
losteric regulation. It has been previously shown that PTMs
and the association of metabolites could change PKM2
oligomerization. Tetramer formation is essential for PKM2
activation, but not all tetrameric PKM2 possess high activity.
Wang et al. showed us an exemption that a patient derived
mutant, PKM2 K422R is a less active tetrameric PKM2. To
understand the mechanism, R- and T-state conformations of
PKM2 were then recognized. Different states of PKM2 con-
fer them distinct activities. Tetramer formation and R-/T-state
transition, the regulation at these two levels provides precise
control of activity of PKM2 in various physiological and
pathological circumstances. Moreover, the “seesaw” model
proposed not only will help us to understand the complexity
of allosteric regulation, but also will provide a platform for
further investigation of other modiﬁcations/mutations of
PKM2, and for the development of new compounds to inhibit
tumor growth based on this R-/T-state transition.
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